IL159843A0 - Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them - Google Patents
Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- IL159843A0 IL159843A0 IL15984302A IL15984302A IL159843A0 IL 159843 A0 IL159843 A0 IL 159843A0 IL 15984302 A IL15984302 A IL 15984302A IL 15984302 A IL15984302 A IL 15984302A IL 159843 A0 IL159843 A0 IL 159843A0
- Authority
- IL
- Israel
- Prior art keywords
- amino
- pharmaceutical compositions
- preparation
- compositions containing
- kinase inhibitors
- Prior art date
Links
- IUBSMBJKUKVEMK-UHFFFAOYSA-N 4-amino-2h-phthalazin-1-one Chemical class C1=CC=C2C(N)=NNC(=O)C2=C1 IUBSMBJKUKVEMK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Manufacturing & Machinery (AREA)
- Neurology (AREA)
- Ceramic Engineering (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Structural Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/922,729 US20030073692A1 (en) | 2001-08-07 | 2001-08-07 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
PCT/EP2002/008544 WO2003014090A1 (en) | 2001-08-07 | 2002-07-30 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159843A0 true IL159843A0 (en) | 2004-06-20 |
Family
ID=25447517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15984302A IL159843A0 (en) | 2001-08-07 | 2002-07-30 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
Country Status (23)
Country | Link |
---|---|
US (2) | US20030073692A1 (de) |
EP (1) | EP1427708B1 (de) |
JP (1) | JP2005501085A (de) |
KR (1) | KR20040029400A (de) |
CN (2) | CN101085759A (de) |
AT (1) | ATE407928T1 (de) |
BR (1) | BR0211807A (de) |
CA (1) | CA2455759A1 (de) |
CO (1) | CO5560573A2 (de) |
CZ (1) | CZ2004305A3 (de) |
DE (1) | DE60228857D1 (de) |
DK (1) | DK1427708T3 (de) |
EA (1) | EA006645B1 (de) |
ES (1) | ES2315385T3 (de) |
IL (1) | IL159843A0 (de) |
MX (1) | MXPA04000905A (de) |
NO (1) | NO20040547L (de) |
NZ (1) | NZ531310A (de) |
PL (1) | PL368440A1 (de) |
PT (1) | PT1427708E (de) |
SI (1) | SI1427708T1 (de) |
WO (1) | WO2003014090A1 (de) |
ZA (1) | ZA200401316B (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
AU2004293017B2 (en) * | 2003-11-19 | 2010-08-19 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US8071579B2 (en) | 2003-12-01 | 2011-12-06 | The Institute Of Cancer Research: Royal Cancer Hospital | DNA damage repair inhibitors for the treatment of cancer |
EP1694686A1 (de) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinaseinhibitoren |
US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1778669A2 (de) * | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase-inhibitoren |
GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
JP2008514636A (ja) * | 2004-09-28 | 2008-05-08 | アンジオン バイオメディカ コーポレイション | サイトカイン活性の低分子モジュレーター |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
KR101292598B1 (ko) * | 2005-01-14 | 2013-08-05 | 질레드 코네티컷 인코포레이티드 | 키나아제 활성 조절제로서의 1,3-디아릴 치환된 우레아 |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
DE102005011822A1 (de) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | Phthalazinone |
US20080318960A1 (en) * | 2005-05-26 | 2008-12-25 | Ethan Burstein | PAR2-modulating compounds and their use |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
JP2009530330A (ja) * | 2006-03-20 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | フタラジノンピラゾール誘導体、その製造および医薬品としての使用 |
JP2009541217A (ja) * | 2006-06-15 | 2009-11-26 | クドス ファーマシューティカルズ リミテッド | Parp阻害剤としての2−オキシベンズアミド誘導体 |
CN101484436A (zh) * | 2006-06-15 | 2009-07-15 | 库多斯药物有限公司 | 作为parp抑制剂的2-氧基杂芳基酰胺衍生物 |
US20090181951A1 (en) * | 2006-06-15 | 2009-07-16 | Kudos Pharmaceuticals Limited | Parp inhibitors |
EP2223925A1 (de) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase-Inhibitoren |
EA200970361A1 (ru) | 2006-10-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы киназы |
UY30639A1 (es) * | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
WO2008061108A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
WO2008104475A1 (en) | 2007-02-27 | 2008-09-04 | Nerviano Medical Sciences S.R.L. | Isoquinolinopyrrolopyridinones active as kinase inhibitors |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
EP2003129B1 (de) | 2007-06-11 | 2017-08-09 | Nerviano Medical Sciences S.r.l. | 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate |
ES2369320T3 (es) * | 2007-10-11 | 2011-11-29 | Glaxo Group Limited | Compuestos de ftalazina y pirido(3,4-d)piridazina como antagonistas del receptor h1. |
CN101821242B (zh) * | 2007-10-17 | 2013-07-24 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮 |
US8772326B2 (en) | 2008-07-10 | 2014-07-08 | Anigion Biomedica Corp. | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
DK2346495T4 (da) | 2008-10-07 | 2023-08-28 | Kudos Pharm Ltd | Farmaceutisk formulering 514 |
WO2010042649A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF |
WO2010042646A1 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof |
US20110098304A1 (en) * | 2008-10-22 | 2011-04-28 | Bijoy Panicker | Small molecule inhibitors of PARP activity |
UY32790A (es) * | 2009-07-15 | 2011-02-28 | Astrazeneca Ab | Compuesto de ftalazinona |
MX2012012052A (es) * | 2010-04-16 | 2013-03-21 | Abbvie Inc | Inhibidores de ftalazin-(2h)-ona de cinasas. |
CN103058927B (zh) * | 2011-10-21 | 2015-04-22 | 华国媛 | 一种喹啉衍生物及其应用 |
JP6545148B2 (ja) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ,エルエルシー | ピリダジノン化合物及び嚢胞性線維症の治療のための方法 |
CN107298640B (zh) * | 2017-07-19 | 2020-08-04 | 曲阜师范大学 | 一种亚甲基酮化合物的制备方法及其应用 |
SG11202110406SA (en) | 2019-04-11 | 2021-10-28 | Angion Biomedica Corp | Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole |
AU2020345899A1 (en) | 2019-09-12 | 2022-03-03 | Mirati Therapeutics, Inc. | MTA-cooperative PRMT5 inhibitors |
WO2023125540A1 (zh) * | 2021-12-27 | 2023-07-06 | 南京明德新药研发有限公司 | 吡唑-1(2h)-酞嗪酮类化合物及其应用 |
CN116903611A (zh) * | 2022-01-26 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用 |
CN116178347A (zh) * | 2022-06-29 | 2023-05-30 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE567431A (de) * | 1957-05-07 | |||
EP0600831A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phthalazinonderivate |
EP0634404A1 (de) * | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazinderivate und deren Verwendung als pestizides Mittel |
JPH0961961A (ja) * | 1995-08-21 | 1997-03-07 | Fuji Photo Film Co Ltd | 熱現像感光材料 |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
EP0875512A3 (de) | 1997-04-16 | 1999-04-07 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | Naphthylpiperazin-Derivate mit antipsychotischer Wirkung |
BR0009650A (pt) * | 1999-04-09 | 2002-01-02 | Meiji Seika Kaisha | Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto |
-
2001
- 2001-08-07 US US09/922,729 patent/US20030073692A1/en not_active Abandoned
-
2002
- 2002-07-30 CN CNA2007101101264A patent/CN101085759A/zh active Pending
- 2002-07-30 JP JP2003519040A patent/JP2005501085A/ja not_active Abandoned
- 2002-07-30 EP EP02758416A patent/EP1427708B1/de not_active Expired - Lifetime
- 2002-07-30 PT PT02758416T patent/PT1427708E/pt unknown
- 2002-07-30 ES ES02758416T patent/ES2315385T3/es not_active Expired - Lifetime
- 2002-07-30 NZ NZ531310A patent/NZ531310A/en unknown
- 2002-07-30 EA EA200400283A patent/EA006645B1/ru not_active IP Right Cessation
- 2002-07-30 SI SI200230738T patent/SI1427708T1/sl unknown
- 2002-07-30 MX MXPA04000905A patent/MXPA04000905A/es unknown
- 2002-07-30 CA CA002455759A patent/CA2455759A1/en not_active Abandoned
- 2002-07-30 CN CNA028154193A patent/CN1538960A/zh active Pending
- 2002-07-30 DK DK02758416T patent/DK1427708T3/da active
- 2002-07-30 KR KR10-2004-7001814A patent/KR20040029400A/ko not_active Application Discontinuation
- 2002-07-30 US US10/486,463 patent/US7432263B2/en not_active Expired - Fee Related
- 2002-07-30 IL IL15984302A patent/IL159843A0/xx unknown
- 2002-07-30 PL PL02368440A patent/PL368440A1/xx not_active Application Discontinuation
- 2002-07-30 CZ CZ2004305A patent/CZ2004305A3/cs unknown
- 2002-07-30 BR BR0211807-6A patent/BR0211807A/pt not_active IP Right Cessation
- 2002-07-30 AT AT02758416T patent/ATE407928T1/de not_active IP Right Cessation
- 2002-07-30 WO PCT/EP2002/008544 patent/WO2003014090A1/en active IP Right Grant
- 2002-07-30 DE DE60228857T patent/DE60228857D1/de not_active Expired - Fee Related
-
2004
- 2004-02-06 NO NO20040547A patent/NO20040547L/no not_active Application Discontinuation
- 2004-02-18 ZA ZA200401316A patent/ZA200401316B/en unknown
- 2004-03-03 CO CO04019499A patent/CO5560573A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200400283A1 (ru) | 2004-08-26 |
PT1427708E (pt) | 2008-11-20 |
ATE407928T1 (de) | 2008-09-15 |
JP2005501085A (ja) | 2005-01-13 |
ZA200401316B (en) | 2005-03-10 |
SI1427708T1 (sl) | 2008-12-31 |
NZ531310A (en) | 2006-02-24 |
CO5560573A2 (es) | 2005-09-30 |
DK1427708T3 (da) | 2008-11-24 |
CN1538960A (zh) | 2004-10-20 |
WO2003014090A1 (en) | 2003-02-20 |
EP1427708A1 (de) | 2004-06-16 |
ES2315385T3 (es) | 2009-04-01 |
KR20040029400A (ko) | 2004-04-06 |
US20050020583A1 (en) | 2005-01-27 |
CA2455759A1 (en) | 2003-02-20 |
BR0211807A (pt) | 2004-09-21 |
MXPA04000905A (es) | 2004-04-02 |
EP1427708B1 (de) | 2008-09-10 |
EA006645B1 (ru) | 2006-02-24 |
DE60228857D1 (de) | 2008-10-23 |
US7432263B2 (en) | 2008-10-07 |
US20030073692A1 (en) | 2003-04-17 |
CN101085759A (zh) | 2007-12-12 |
PL368440A1 (en) | 2005-03-21 |
CZ2004305A3 (cs) | 2004-08-18 |
NO20040547L (no) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159843A0 (en) | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
MXPA04001114A (es) | Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
MXPA02012164A (es) | Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
MXPA04000920A (es) | Derivados de aminoisoxazol activos como inhibidores de la cinasa. | |
GB0102687D0 (en) | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them | |
AU2003218989A1 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
CA2486101A1 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
GB0330043D0 (en) | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them | |
MXPA05009719A (es) | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
GB0330042D0 (en) | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them | |
MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
EA200200249A1 (ru) | Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов | |
AU2002359164A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |